Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK104 in Metastatic Nasopharyngeal Carcinoma
CTR20192735Phase 2Completed
- Sponsor
- Akeso, Inc.
- Start
- Feb 2020
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of cadonilimab in nasopharyngeal carcinoma (NPC), sponsored by Akeso, Inc.. Started Feb 2020; status: completed.
02
Drugs
cadonilimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on CTR20192735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192735.